These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 10027726)

  • 1. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.
    Rawstron A; Barrans S; Blythe D; Davies F; English A; Pratt G; Child A; Morgan G; Jack A
    Br J Haematol; 1999 Jan; 104(1):138-43. PubMed ID: 10027726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
    Ak I; Aslan V; Vardareli E; Gülbaş Z
    Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
    Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
    Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
    Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
    Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
    Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
    Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
    Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
    Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
    Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Kovarova L; Buresova I; Buchler T; Suska R; Pour L; Zahradova L; Penka M; Hajek R
    Neoplasma; 2009; 56(6):526-32. PubMed ID: 19728762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
    Klimienė I; Radzevičius M; Matuzevičienė R; Sinkevič-Belliot K; Kučinskienė ZA; Pečeliūnas V
    Int J Lab Hematol; 2021 Jun; 43(3):403-408. PubMed ID: 33185981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
    Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
    Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
    Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
    Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
    Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
    Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.